Cargando…

Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic

The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a grea...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Yongming, Lipkovich, Ilya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117454/
https://www.ncbi.nlm.nih.gov/pubmed/33983621
http://dx.doi.org/10.1007/s43441-021-00297-6
_version_ 1783691588793270272
author Qu, Yongming
Lipkovich, Ilya
author_facet Qu, Yongming
Lipkovich, Ilya
author_sort Qu, Yongming
collection PubMed
description The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a great deal of discussion on amending protocols and statistical analysis plans to address these issues. In this article, we revisit recent research on estimands and handling of missing values, especially the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. Based on an in-depth discussion of the strategies for handling ICEs using a causal inference framework, we suggest some improvements in applying the estimand and estimation framework in ICH E9 (R1). Specifically, we discuss a mix of strategies allowing us to handle ICEs differentially based on reasons for ICEs. We also suggest ICEs should be handled primarily by hypothetical strategies and provide examples of different hypothetical strategies for different types of ICEs as well as a road map for estimation and sensitivity analyses. We conclude that the proposed framework helps streamline translating clinical objectives into targets of statistical inference and automatically resolves many issues with defining estimands and choosing estimation procedures arising from events such as the pandemic.
format Online
Article
Text
id pubmed-8117454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81174542021-05-13 Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic Qu, Yongming Lipkovich, Ilya Ther Innov Regul Sci Analytical Report The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a great deal of discussion on amending protocols and statistical analysis plans to address these issues. In this article, we revisit recent research on estimands and handling of missing values, especially the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. Based on an in-depth discussion of the strategies for handling ICEs using a causal inference framework, we suggest some improvements in applying the estimand and estimation framework in ICH E9 (R1). Specifically, we discuss a mix of strategies allowing us to handle ICEs differentially based on reasons for ICEs. We also suggest ICEs should be handled primarily by hypothetical strategies and provide examples of different hypothetical strategies for different types of ICEs as well as a road map for estimation and sensitivity analyses. We conclude that the proposed framework helps streamline translating clinical objectives into targets of statistical inference and automatically resolves many issues with defining estimands and choosing estimation procedures arising from events such as the pandemic. Springer International Publishing 2021-05-13 2021 /pmc/articles/PMC8117454/ /pubmed/33983621 http://dx.doi.org/10.1007/s43441-021-00297-6 Text en © The Drug Information Association, Inc 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Analytical Report
Qu, Yongming
Lipkovich, Ilya
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title_full Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title_fullStr Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title_full_unstemmed Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title_short Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
title_sort implementation of ich e9 (r1): a few points learned during the covid-19 pandemic
topic Analytical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117454/
https://www.ncbi.nlm.nih.gov/pubmed/33983621
http://dx.doi.org/10.1007/s43441-021-00297-6
work_keys_str_mv AT quyongming implementationofiche9r1afewpointslearnedduringthecovid19pandemic
AT lipkovichilya implementationofiche9r1afewpointslearnedduringthecovid19pandemic